Treatment-Resistant Major Depressive Disorder

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Compass Pathways
Compass PathwaysUK - Cheshire
1 program
1
PsilocybinPhase 2
Compass Therapeutics
1 program
1
PsilocybinPhase 21 trial
Active Trials
NCT05381974WithdrawnEst. Jun 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Compass TherapeuticsPsilocybin

Clinical Trials (1)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start: Sep 2022Est. completion: Jun 2023
Phase 2Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space